Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

T-794: a MAO-A inhibitor with antidepressant activity

April 20, 1998

Phase I data reported on CoCensys' ganaxolone tablet formulation

April 17, 1998

Allelix gets go-ahead to start U.K. trials for antimigraine drug

April 17, 1998

OGS and Pfizer to collaborate on Alzheimer's disease research

April 17, 1998

Ampligen to be evaluated in U.S. phase III trials for chronic fatigue syndrome

April 17, 1998

Novel dopaminergic compounds in the pipeline at ADIR

April 17, 1998

Another H3 antagonist in the pipeline at Gliatech

April 16, 1998

DuPont Merck presents a novel CRF-R1 antagonist for anxiety and depression

April 16, 1998

Meiji Seika presents 5-HT7 antagonist DR-4004

April 16, 1998

Kynurenine 3-monooxygenase inhibitors under study at P&U as neuroprotectants

April 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...